Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28536924 | 0.80 | CYP2A6 (0.53) | CYP2A6PYCR1GRM5MAPK14ITK | |
| SCHEMBL24040098 | 0.79 | GRM5 (0.44) | PYCR1TAAR1GRM5ALDH1A1MAPK1 | |
| SCHEMBL16942774 | 0.79 | CYP2A6 (0.51) | CYP2A6GRM5MAPK14ALDH1A1CHRNB2 | |
| SCHEMBL13242886 | 0.79 | CYP2A6 (0.51) | CYP2A6PYCR1MAPK14ALOX5 | |
| SCHEMBL1239417 | 0.77 | PYCR1 (0.56) | CYP2A6PYCR1TAAR1ALDH1A1 | |
| SCHEMBL8136691 | 0.77 | CYP2A6 (0.61) | CYP2A6PYCR1GRM5ALDH1A1KDM4E | |
| SCHEMBL30450598 | 0.76 | HRH3 (0.47) | PYCR1GRM5ALDH1A1MAPK1CHRNB2 | |
| SCHEMBL13094169 | 0.76 | CYP2A6 (0.49) | CYP2A6PYCR1MAPK14ALDH1A1ITK | |
| SCHEMBL1375869 | 0.76 | GRM5 (0.53) | TAAR1GRM5ALDH1A1MAPK1 | |
| SCHEMBL29779956 | 0.76 | GRM5 (0.53) | TAAR1GRM5ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2151447-A1 | LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Meiji Seika Kaisha Ltd. (JP) | 2010-02-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | CYP2A6 660/4885PYCR1 258/4885TAAR1 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.